Lonza start commercial operations in newly expanded facility
Lonza Small Molecules adds new capabilities to their expanded facility in China, enabling smoother transitions between small and large scale manufacturing.
Lonza have started new operations at their recently expanded API manufacturing facility in Nansha, China, as part of the CHF 20 million investment in 2021.
The addition of mid-scale manufacturing assets include six 1,000 L reactors, four 1,500 L reactors, and isolation equipment, which will span the gap between early- and late-phase production. The new equipment and more seamless transitions between phases will provide a better service to the customers looking to move through small-scale manufacturing to large scale, all whilst maintaining high standard of quality in line with regulatory standards.
The site provides an integral part of Lonza’s Small Molecules manufacturing network. The team based in Nansha work for customers around the world, mainly focusing on API development. The facility also works hard to ensure regulatory standards are met throughout the drug development process and all the way through scaling up. The team includes regulatory specialists with experience working to Chinese regulatory standards.
The developments at the facility have opened up 70 new positions, bringing the numbers of employees to around 330.
Jan Vertommen, Executive Director, Global Head of Sales, Small Molecules, Lonza commented:
“This mid-scale API manufacturing expansion provides a cost-effective, seamless way to move small molecule compounds to commercial manufacturing according to global quality and regulatory standards. Global pharma and biotech companies are increasingly looking to China for their development and manufacturing needs and - in some cases - for greater access to clinical trials conducted in the region. The expanded capabilities at our Nansha site enable us to continue supporting global customers in developing and manufacturing the next generation of treatments.”
Related News
-
News Biotheus partners with BioNTech to take their anti-tumour therapy global
Innovative biotech company Biotheus has signed a deal with BioNTech to manufacture, market, and distribute their latest anti-tumour therapy around the world. -
News Roche acquires rights to Zion Pharma's HER2-positive breast cancer therapeutic
Roche launches into a new agreement with Zion Pharma, a leading Chinese pharmaceutical company, to help develop and commercialise their flagship small molecule tyrosine kinase inhibitor, ZN-A-1041. -
News 2023 Lunar New Year Round-up: Biopharma in the APAC region
With the Lunar New Year ushering in celebrations for the pharmaceutical community around the world on Sunday January 22, 2023, we’ve rounded up some of the top CPHI Online articles and reports from the last year looking at pharmaceutical markets ... -
News Thermo Fisher Scientific expands with state-of-the-art facility in China
Thermo Fisher Scientific are to open a new cGMP facility in China, including the latest technology so that they can assist in the accelerated provision of medicines to patients. -
News Chinese market represents ‘single greatest generational opportunity’ for Pharma
China’s pharmaceutical industry is changing from formerly generics-focused into one that emphasizes innovation, spurred by shifting government policy and an aging population. -
News Sharp seeks greater foothold in Chinese market through ClinsChain partnership
Sharp hopes teaming up with clinical service provider ClinsChain will open the door to the Chinese market -
News WuXi STA launches new HPAPI production facility in China
The new plant features flow chemistry and milling technology, as well as reactors up to 3,000 liters -
News Mitigating supply risk: Having feet on the ground during COVID-19
Having personnel on the ground may be central to mitigating supply chain risks, even as the world embraces the remote approach.
Position your company at the heart of the global Pharma industry with a CPHI Online membership
-
Your products and solutions visible to thousands of visitors within the largest Pharma marketplace
-
Generate high-quality, engaged leads for your business, all year round
-
Promote your business as the industry’s thought-leader by hosting your reports, brochures and videos within your profile
-
Your company’s profile boosted at all participating CPHI events
-
An easy-to-use platform with a detailed dashboard showing your leads and performance